Produit
AGENTS IA
APPLICATIONS DE L'IA
AUTRES
Solutions
SECTEURS D'ACTIVITÉ
Tarification
Ressources
EXPLORER
ENGAGER
ASSISTANCE ET SERVICES
À propos
Plateforme PatSnap Eureka
Mandataires en propriété intellectuelle
Agents pour l'ingénierie
Agents pour les sciences de la vie
Agents pour matériaux
Analytique
Intelligence IPSynapse
Renseignement biopharmaceutiqueBiographie
Recherche et analyse de séquences biologiquesChimique
Recherche et analyse de structures chimiquesEureka AI à l'intérieur
Services professionnels
Témoignages clients
Blog
Rapport mondial sur l'innovation
Glossaire
Newsroom
Webinaires et formations
Frontière
Communauté d'utilisateurs
Confiance et sécurité
PatentBench
LLM
Centre d'aide
Carrières
Accès à plus de 2 000 000 000 points de données structurées dans les domaines des brevets, des sciences, des litiges et des technologies.
Innovez 75 % plus vite à un coût réduit de 25 %.
Cloud ou sur site pour une confidentialité et un contrôle maximaux
Reconnu par plus de 18 000 innovateurs à travers le monde
Pour l'utiliser, cliquez sur le bouton de vérification dans l'e-mail que nous avons envoyé à [email protected].
Cela contribue à sécuriser votre compte.
Vous devriez le recevoir sous peu. N'oubliez pas de vérifier votre dossier spam.
Unlock professional features and history
Already have an account? Log In
To start using PatSnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Série soigneusement sélectionnée offrant des informations précieuses aux professionnels de l'innovation.
Article | Rapport How closed-loop quality control, fracture-mechanics thresholds, and inter-process correlation enable zero-defect manufacturing in high-volume automotive stamping.
Article | Rapport Explore next-generation smoking cessation drugs: nicotinic receptor partial agonists, 5-HT2C agonists, anti-nicotine antibodies, cannabinoids, and botanical approaches in the patent pipeline.
Article | Rapport How machine learning-based tool wear prediction maintains surface finish consistency in hard turning of bearing steel — patent analysis of 60+ filings.
Article | Rapport Explore the knee osteoarthritis drug pipeline: GLP-1 agonists, dual IL-1α/β blockade, NLRP3 inhibitors, and intraarticular delivery platforms from Novartis, AbbVie, INSERM and more.
Article | Rapport How do engineers reduce oxidation-induced embrittlement in refractory high-entropy alloys for hypersonic thermal protection? Patent evidence, coating strategies, and design principles explained.
Article | Rapport How can engineers reduce oxidation-induced embrittlement in refractory high-entropy alloys for hypersonic thermal protection? Patent-backed strategies analysed.
Article | Rapport How do open rotor engines compare to geared turbofan for short-haul decarbonization? Bypass ratios, TSFC data, noise trade-offs, and hybrid pathways analysed.
Article | Rapport How RNAi, ASO, and GalNAc-siRNA approaches target angiotensinogen (AGT) to treat resistant hypertension — patent landscape, clinical signals, and key findings.
Article | Rapport How do open rotor engines compare to geared turbofans for short-haul decarbonization? Bypass ratios, TSFC data, noise trade-offs, and hybrid-electric pathways analysed.
Article | Rapport How to validate AI perception systems under ISO 21448 SOTIF for highway pilot: patent intelligence on XAI, sensor fusion, residual risk, and scenario testing.
Article | Rapport How sodium channel modulators, potassium channel openers, and gene therapy are reshaping the epilepsy drug pipeline for refractory and rare genetic epilepsies.
Article | Rapport How sodium channel modulators, potassium channel openers, and gene therapy are reshaping the epilepsy drug pipeline for refractory and rare genetic seizure disorders.
Article | Rapport Explore the ADHD drug pipeline: non-stimulant mechanisms, extended-release formulations, and adult ADHD approaches — from mGluR activators to KDM1A inhibitors.
Article | Rapport How sparse attention mechanisms cut transformer inference costs by eliminating O(n²) bottlenecks. Patent-backed analysis of masking, token compression & more.
Article | Rapport Survey of non-opioid CLBP drug pipeline: anti-NGF antibodies, central sensitization targets, dual biologics, and emerging nucleic acid approaches. 12 modalities mapped.